Navigation Links
Algeta Demonstrates Targeted Cancer-killing Potential of Novel,Alpha Particle Linked Antibodies in Leading Medical Journal Blood

nt, well-tolerated and convenient to use.

Algeta's lead product candidate, Alpharadin, is expected to enter Phase III clinical trials in hormone refractory prostate cancer based on positive Phase II results. Alpharadin is a novel bone-seeking therapeutic based on the alpha particle emitter radium-223 and may target skeletal metastases from multiple cancer types, as well as primary bone cancers.

Algeta is also developing other technologies for delivering alpha emitters. These include microparticles, liposomes, and methods to enhance the potency of therapeutic antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227.

The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).

Alpharadin and Algeta are trademarks of Algeta ASA.

Forward-looking Statement

This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of operations and the financial condition of Algeta. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Theses factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to close viable and profitable business deals, the risk of non-approval of patents not yet granted and difficulties of obtaining relevant governmental approvals for new products

###

This content was distributed through Hugin - connecting communication professionals/with their target audience. Visit us at
'"/>





Page: 1 2 3 4

Related medicine technology :

1. Algeta to Present Phase II Clinical Study Data for Alpharadin in Prostate Cancer at ASCO
2. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
9. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
10. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
11. Lpath Demonstrates First-in-Class AMD Results With Its Lead Drug Candidate, Sphingomab
Post Your Comments:
(Date:3/4/2015)... XBiotech announced today that results from ... moderate to severe plaque psoriasis have been published ... evaluated the potential benefit of MABp1, the Company,s ... (IL-1a). IL-1a is a pro-inflammatory cytokine present in ... The Company claims that blockade of IL-1a can ...
(Date:3/4/2015)... 4, 2015   Mayo Clinic and ... the next generation of wearable biosensors designed to fight ... this technology will be game-changer. These patch biosensors may ... James Levine, M.D., Ph.D. , a Mayo Clinic ... and can be integrated into the care people receive." ...
(Date:3/4/2015)... 2015 From March 8-11, 2015 Excellis ... Management Conference and Expo in Orlando, ... supply chain education event, attended by nearly 500 ... the pharmaceutical distribution industry moving. Attracting thought-provoking speakers, ... issues important to healthcare distribution and technology, logistics ...
Breaking Medicine Technology:XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology 2Mayo Clinic and Gentag, Inc. Announce Agreement To Develop Wireless Sensors for Treatment of Obesity and Diabetes 2Mayo Clinic and Gentag, Inc. Announce Agreement To Develop Wireless Sensors for Treatment of Obesity and Diabetes 3
... 2011 The makers of MigreLief , the world,s most ... the popular nationally broadcast Lifetime series, " The Balancing Act." ... a.m. et/pt) this informative and entertaining show that provides a ... will feature the first name in migraine relief, MigreLief. ...
... 2011 Caraco Pharmaceutical Laboratories Ltd. (NYSE Amex: CPD)(Caraco) ... on June 14, 2011, Caraco,s stockholders voted to approve ... among Sun Pharmaceutical Industries Limited ("Sun Pharma"), Sun Pharma ... and Caraco dated as of February 21, 2011. Immediately ...
Cached Medicine Technology:MigreLief Now On Lifetime T.V.'s "The Balancing Act" Airing June 20th & July 25th 2Caraco Announces Stockholder Approval of Merger Agreement with Sun Pharma and Consummation of the Merger 2Caraco Announces Stockholder Approval of Merger Agreement with Sun Pharma and Consummation of the Merger 3
(Date:3/5/2015)... 2015 Elandas announces the creation of ... the company prepares to announce its next generation product ... in the Life Sciences field. , “Elandas depends on ... Elandas CEO Ryan Roberts. “We have been fortunate to ... our collaborative efforts. As we continue to grow, we ...
(Date:3/4/2015)... The emergence of nanotechnology has ... past decade. The pharmaceutical world has witnessed advancements ... the form of liposomes and polymeric nanoparticles that ... safety and efficiency. In the area of ... upon the enhanced permeability and retention (EPR) effect ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Ultraman Florida ... 6.2 mile swim, 261.4 mile bike, and 52.4 mile ... total time of 24:45:45. , "This race was awesome ... my wonderful team and sponsors for supporting me through ... Florida 2015 had a total of 40 select participants ...
(Date:3/4/2015)... March 04, 2015 TROY Healthcare Solutions ... which provides the ultimate level of security for prescriptions, ... Hilton Houston Plaza Medical Center located at 6633 Travis ... Beginning at 7 AM, TROY Healthcare Solutions will host ... Solutions will offer brief presentations each hour to introduce ...
(Date:3/4/2015)... NY (PRWEB) March 04, 2015 Smokers ... breakthrough marketing campaign called 'We Love Smokers' from Aqua-Tine, ... for tobacco. , "It’s important to establish a ... true to it. Our idea, 'We Love Smokers' elevates ... point of view. We created a bold tone of ...
Breaking Medicine News(10 mins):Health News:Elandas Creates Advisory Board to Help Guide Innovation 2Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 2Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 3Health News:Living Fuel Champion Christian Isakson Finishes Second In UltraMan Florida Test of Endurance 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 3Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 2Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 3
... RIO DE JANEIRO, Dec. 9 Amilpar (Bovespa: ... the largest managed,care organization in Brazil, in addition to the ... informs its shareholders and the,market that the initiatives to proceed ... Applicant its subsidiary AMIL ASSISTENCIA MEDICA,INTERNACIONAL LTDA. The filing to ...
... SANTA ROSA, Calif., Dec. 9 Kendall-Jackson Winery today ... for Cancer Research, concluding its five-month-long, online auction of ... from champion racehorse Rachel Alexandra,s historic 2009 racing season. ... The highest-earning single item was the final lot: a ...
... same as last year, survey shows , WEDNESDAY, Dec. 9 (HealthDay ... of the flu in general, there has been only a slight ... flu shot, a new report shows. , By the middle of ... is recommended had gotten a shot, according to the survey. Seasonal ...
... Dec. 9 The Michigan Minority Business Development Council ... On September 29 at the Detroit Symphony Orchestra/Max Fisher Music ... The theme for this year,s awards was: "Celebrating the ... corporations and individuals who actively include certified minority suppliers in ...
... , SOUTHFIELD, Mich., Dec. 9 Blue Care Network has announced ... be retiring at the end of February after a 33-year career ... Cross Blue Shield of Michigan. , The company will ... , "Jeanne has led the way for Blue Care Network ...
... , ... today announced a C$22.5 million project with the Government of ... of an electronic healthcare records (EHR) system. This technology can ... information, which can improve the efficiency and quality of patient ...
Cached Medicine News:Health News:Rachel Alexandra, Kendall-Jackson Donate $20,000 to V Foundation for Cancer Research 2Health News:Seasonal Flu Vaccination Rates Still Too Low 2Health News:Seasonal Flu Vaccination Rates Still Too Low 3Health News:Mike Lucas of GE Healthcare Recognized as the Lifeline for Minority Businesses; Receives the MMBDC 2009 President's Award 2Health News:Blue Care Network CEO Jeanne Carlson to Retire at the End of February 2010 2Health News:IBM Chosen to Build System for Electronic Health Records in Manitoba for Improved Patient Care 2Health News:IBM Chosen to Build System for Electronic Health Records in Manitoba for Improved Patient Care 3
... The microprocessor controlled, Blanketrol ... therapy system provides effective patient ... one system! The Blanketrol II ... highest flow rates of any ...
Inquire...
Inquire...
... and accurate immunoassay for the quantification of ... fully automated Elecsys proBNP assay helps to ... NT-proBNP levels also indicate the severity of ... prognosis. In addition, NT-proBNP facilitates monitoring, allowing ...
Medicine Products: